Tag: NY

Poster-Psychosocial Factors

Multiple Sclerosis, Patient Reported Meaning and Purpose: The Relationship of Physical Ability to Patient Reported Quality of Life

Background: Multiple Sclerosis (MS) is an autoimmune disease characterized by relapses, progression, physical disability and MRI changes....

Read More

Poster-Programs

Knowledge, Skills, and Confidence of Healthcare Professionals Participating in the Echo MS Program

Background: ECHO MS is a videoconference-based education and case-consultation program that seeks to expand MS expertise. In Fall 2020, the...

Read More

Poster-Methods of Care

Psychoanalytic Telepsychology with MS Patients and Their Support People

Background: N/A Objectives: N/A Methods: N/A Results: N/A Conclusions: N/A This is not a Research-based presentation abstract. I would like...

Read More

Poster-Multidisciplinary Care

Association between Patient Reported Outcomes and Gait in People with Multiple Sclerosis with Differing Disabilities

Background: Multiple Sclerosis (MS) is a disease characterized by ambulation deficits, fear of falling and subjective fatigue. Altered...

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Disease-modifying Therapy

Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study

Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...

Read More

Poster-Disease-modifying Therapy

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease

Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...

Read More

Poster-Disease-modifying Therapy

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More

Poster-Disease-modifying Therapy

Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More

Poster-Disease-modifying Therapy

Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis

Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...

Read More